Company intelligence / Profile preview

SBI Ventures

Minato-ku, Tokyo, Tokyo-to, Japansbiventures.co.in ↗

Ownership: Private
Employees: ~22
Development stage: Other

Overview

Most programs are licensed out at preclinical or early clinical stages. Anti‐ILT7 antibody (VIB7734) entered Phase I trials via Viela Bio/MedImmune. Other candidates such as SBI‐9674 and SBI‐3150 have been licensed to Kyowa Kirin and Asahi Kasei Pharma, respectively, with development ongoing under those partners.

Therapeutic areas: ImmunologyOncology
Modalities: Monoclonal antibodySmall moleculeNucleic acid drugCell therapyNutraceuticals
Industry: Investors

Partnerships

Viela Bio / MedImmuneKyowa KirinAsahi Kasei PharmaHelixir

Beyond the preview

Go deeper on SBI Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBI Ventures.

Explore the full profile